title: [Elimination of Helicobacter pylori in patients with recurrent abdominal pain with simultaneous administration of ranitidine, bismuth subsalicylate and clarithromycin].
abstract: OBJECTIVE
  Elimination of Helicobacter pylori with Chlaritromicin, Bismuth subsalicylate and Ranitidine; and improvement of recurrent abdominal pain. ANTECEDENT: Different antibiotics, antagonist H2 and others has been used for elimination and, or eradication of Helicobacter pylori.
  
  
  METHODS
  22 children with recurrent abdominal pain associated to gastritis and histologic identification of Helicobacter pylori were studied under a period of 18 months (january 1992 to june 1993), at Instituto Nacional de Pediatría, México, D:F: All children were treated simultaneously with: Chlaritromicin, 15 days, Plus ranitidine and bismuth subsalicylate for one month.
  
  
  RESULTS
  Helicobacter pylori was eliminate in 14 of 22 children studied. All these children had an important improvement of recurrent abdominal pain.
  
  
  CONCLUSIONS
  Elimination of Helicobacter pylori and clinical improvement was present in 14 of 22 children studied (63.7%).
authors.affiliation: Servicio de Gastroenterología y nutrición, Instituto Nacional de Pediatría, México, DF.
authors.forename: J A
authors.initials: JA
authors.lastname: Ramirez Mayans
authors.forename: E
authors.initials: E
authors.lastname: Zamora Davila
authors.forename: R
authors.initials: R
authors.lastname: Cervantes Bustamante
authors.forename: N
authors.initials: N
authors.lastname: Mata Rivera
authors.forename: I
authors.initials: I
authors.lastname: Oyervides Garcia
authors.forename: S
authors.initials: S
authors.lastname: Cuevas
authors.forename: F E
authors.initials: FE
authors.lastname: Zarate Mondragón
mesh_terms: D015746:Abdominal Pain / Q000382:microbiology*; D000897:Anti-Ulcer Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001729:Bismuth / Q000494:pharmacology* / Q000627:therapeutic use; D002648:Child; D017291:Clarithromycin / Q000494:pharmacology* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005756:Gastritis / Q000188:drug therapy* / Q000382:microbiology; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006635:Histamine H2 Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D011446:Prospective Studies; D011899:Ranitidine / Q000494:pharmacology* / Q000627:therapeutic use; D012008:Recurrence
chemical_list: D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D011899:Ranitidine; D017291:Clarithromycin; C010804:bismuth subnitrate; D001729:Bismuth